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Abstract
Background: Toll-like receptors (TLRs) are among the first-line sentinels for immune detection and responsiveness to
pathogens. The TLR2 subfamily of TLRs (TLR1, TLR2, TLR6) form heterodimers with each other and are thus able to recognize a
broad range of components from several microbes such as yeast, Gram-positive bacteria and protozoa. Until now, TLR2
activation by bacterial ligands has long been associated with pro-inflammatory cytokines but not type I interferon responses.
Methodology/Principal Findings: Using a variety of transgenic mice, here we provide in vivo and in vitro data showing that
TLR2 activation does in fact induce interferon-beta and that this occurs via MyD88-IRF1 and -IRF7 pathways. Interestingly, by
microscopy we demonstrate that although a cell surface receptor, TLR2 dependent induction of type I interferons occurs in
endolysosomal compartments where it is translocated to upon ligand engagement. Furthermore, we could show that
blocking receptor internalization or endolysosomal acidification inhibits the ability of TLR2 to trigger the induction type I
interferon but not pro-inflammatory responses.
Conclusion/Significance: The results indicate that TLR2 activation induces pro-inflammatory and type I interferon responses
from distinct subcellular sites: the plasma membrane and endolysosomal compartments respectively. Apart from identifying
and characterizing a novel pathway for induction of type I interferons, the present study offers new insights into how TLR
signaling discriminates and regulates the nature of responses to be elicited against extracellular and endocytosed microbes.
These findings may also have clinical implication. Excessive production of pro-inflammatory cytokines and type I IFNs
following activation of TLRs is a central pathologic event in several hyper-inflammatory conditions. The discovery that the
induction of pro-inflammatory and type I IFN responses can be uncoupled through pharmacological manipulation of
endolysosomal acidification suggests new avenues for potential therapeutic intervention against inflammations and sepsis.
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Introduction
Pattern recognition receptors (PRRs) serve as first-line sentinels
for immune detection of pathogens. To date, the best character-
ized PRRs are the Toll-like receptors (TLRs) expressed either on
the cell surface (TLR1, 2, 4, 5, 6 and 11) or on endosomal
membranes (TLR3, 7, 8 and 9) [1]. Stimulation of TLRs triggers
activation of MyD88-dependent signaling pathways as well as
TRIF-dependent pathways that are unique to TLR3 and TLR4
[2,3,4]. These pathways activate various transcription factors like
NF-kB, AP-1 and/or interferon regulatory factors (IRFs). This
results in the transcription of genes encoding pro-inflammatory
cytokines, chemokines and/or type I interferons (IFNs) that
orchestrate anti-bacterial and anti-viral responses [2,5,6].
Although originally discovered based on their ability to interfere
with viral replication, type I IFNs are also produced in response to
bacterial and even parasitic infections [5,7]. Type I IFNs
encompass a family of more than 13 IFN-a isotypes, a single
IFN-b isotype, and others, such as IFN-v,- e and -k [5,6,8,9].
They all signal through a common two-chain receptor (IFNAR)
and activate a large set of IFN-inducible genes that exert widely
overlapping pleiotropic immunomodulatory effects central to the
activation of innate and adaptive immunity.
Of the PRRs, broadly, two categories of receptors are known to
induce type I IFNs: the transmembrane TLRs and the cytosolic
receptors [5,8]. The latter include the RIG-I helicase and MDA5
which recognize cytosolic RNA and DNA [5,8,10,11]
The TLR2 subfamily of receptors (TLR2/TLR1 and TLR2/
TLR6 heterodimers) recognizes a broad range of cell surface
components from yeast, Gram-positive bacteria, viruses and even
protozoa [5,12]. By virtue of their cell surface localization, in
principle, these receptors are among the first to interact with and
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far,these receptors have been assumed to elicit pro-inflammatory
but not type I interferon responses in response to activation by
bacterial ligands, [13,14,15,16,17,18]. We now show that ligands
for TLR2/1 and TLR2/6 heterodimers do induce type I IFN
responses. Although a cell surface receptor, we observed that upon
activation, TLR2 is internalized and transported into endolysoso-
mal compartments from where it induces interferon-b via MyD88-
IRF1 and IRF7 dependent pathways. Consequently, inhibition of
receptor internalization or endosomal acidification could block the
induction of IFN-b and IFN-inducible genes but not pro-
inflammatory cytokines like TNF-a. This suggests that TLR2
activation induces pro-inflammatory and type I interferon
responses from distinct sub-cellular sites: the plasma membrane
and endolysosomal compartments, respectively. The spatio-
temporal diversification of TLR2 signaling offers new insights
into how TLR signaling discriminates and regulates the nature of
responses to be elicited against extracellular and endocytosed
microbes.
Results
TLR2 induces type I IFN responses
TLR2 activation by bacterial ligands is generally assumed to
induce the transcription of canonical NF-kB dependent pro-
inflammatory cytokines but not type I interferons (IFNs) or
interferon-inducible genes [13,14,15,16,17]. However, when we
stimulated bone marrow derived macrophages (BMDMs) we
noted that besides pro-inflammatory cytokines like TNF-a and IL-
12 (Fig. 1A and D), ligands for TLR2/TLR1 (PAM3CSK4) and
TLR2/TLR6 (MALP-2, PAM2CSK4), could also trigger the
induction of type I IFN-inducible genes; IP-10 (CXCL-10), MX-2,
IL-6 and iNOS (for NO production) (Fig. 1B, E and Fig. S1).
An initial interpretation of type I IFN responses elicited by
TLR2 ligands was contamination. To rule out such a possibility,
macrophages from TLR2
2/2 and MyD88
2/2 mice were analyzed.
Indeed, TLR2 ligands elicited no response in TLR2
2/2 and
MyD88
2/2 macrophages (Fig. 1A–F and Fig. S1). We also
analyzed macrophages from mice deficient in IFN-b or the type I
interferon receptor (IFNAR). IFN-b
2/2 and IFNAR
2/2 macro-
phages were impaired in the induction of type I IFN-dependent
genes IP-10, MX-2, iNOS and IL-6 but not in the pro-
inflammatory cytokines TNF-a or IL-12 (Fig. 1A, B, D, E and
Fig. S1). Interestingly, the impairment in IFN-b
2/2 macrophages
was equivalent to that in IFNAR
2/2 macrophages (Fig. 1B, E,
and Fig. S1). Since the IFNAR is a common receptor for all type I
IFNs, this observation suggested that the type I IFN-dependent
responses induced by such agonists was largely due to the activity
of IFN-b and not the other isotypes like IFN-as.
This prompted us to test for IFN-b induction. Quantitative real-
time RT-PCR and ELISA assays demonstrated that all the TLR2
ligands tested could trigger the transcription and subsequent
secretion of IFN-b in a TLR2-MyD88 dependent manner (Fig. 1C
and F). Intriguingly, IFNAR
2/2 macrophage cultures were
repeatedly found to contain more IFN-b (Fig. 1F). Such difference
was however not reflected at the mRNA levels (Fig. 1C),
suggesting that higher levels of IFN-b in IFNAR
2/2 cultures was
due to lack of consumption via IFNAR. Taken as a whole, these
results show that activation of the TLR2-MyD88 pathway leads to
the production of IFN-b which in turn induces type I IFN-
dependent responses.
These findings are contrary to several previous studies
[14,15,16,17]. However, recently, while this study was under
consideration elsewhere, Barbalat and co-workers could show
TLR2 - driven type I IFN responses but only toward viral and not
bacterial ligands [18]. Whereas the explanation for the previous
Figure 1. TLR2 directly induces pro-inflammatory and type I IFN dependent responses via MyD88. WT, TLR2
2/2, MyD88
2/2, IFN-b
2/2
and IFNAR1
2/2 macrophages were stimulated with 1.5 mg/ml of MALP-2 or PAM2CSK4 or PAM3CSK4 then analyzed 6 h later by real-time RT-PCR for
mRNAs of TNF-a (A), IP-10 (B), Mx-2 (E) and IFN-b (C). In parallel, culture supernatants of cells stimulated for 24 h or 10 h were analyzed by ELISA for
concentrations of IL-12p70 (D) or IFN-b (F) respectively. Data are representative of at least three independent experiments (mean 6 s.e.m).
doi:10.1371/journal.pone.0010250.g001
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certain, several factors including sub-optimal activation of TLR2,
low sensitivity of assays and/or measuring type I IFN response off
peak period could have been responsible. For example low
concentrations of TLR2 ligands and sub-optimal northern blotting
and RT-PCR conditions detecting only very strong responses
could account for some of the previous observations [14,15,17,18].
For instance, it is well known, and also shown herein (Fig. 2A and
Fig S2A), that TLR ligands induce IFN-b with a rapid kinetic with
mRNA peaks between 1 and 6 hours post stimulation followed by
a rapid decline to near basal level by 12 hour post stimulation. In
the study by Barbalat and colleagues, the conclusions that bacterial
TLR2 ligands do not induce type I IFNs were largely based on
experiments measuring IFN-b transcript 12–24 hours–a time
window not optimal for detection of IFN-b transcript. The fact
that IFN-b induced by vaccinia virus could be detected at this time
point is probably a reflection of the potential difference in the
kinetics with which the purified TLR ligand and whole
microorganisms (in this case vaccinia virus) interacts with the host
cells. On the other hand, while Toshchakov and co-workers [17]
also concluded that TLR2 ligands do not induce type I IFNs in
bone marrow macrophages, a critical analysis of their data
suggests otherwise. Albeit lower than that by LPS, the authors
could detect TLR2 driven transcriptional upregulation of IFN-b
and the IFN dependent genes iNOS (Figure 5a and 1 respectively
of that paper). The inability to also detect clear response for the
other type I IFN genes like IP-10 could be due to low sensitivity of
assays probably optimal for the detection of stronger responses
triggered via TLR4 and not TLR2. A similar argument could also
account the PCR and northern blot data in the other previous
studies [14,15]. In short, several reasons could account for the
poor detection of TLR2-driven type I IFNs responses in previous
studies and the explanations may vary from one experiment/study
to another. Equally noteworthy, as we have shown herein (Fig. 1F)
the fact that secreted IFN-b is rapidly depleted from the system via
IFNAR could probably have undermined its detection in other
previous studies. This is especially so if assayed long after the peak
of production.
TLR2 induces IFN-b directly
We also tested whether TLR2 induces IFN-b directly as
opposed to a delayed response via auto/paracrine mechanisms.
To that end, first, we did a time course analysis by real-time RT-
PCR, to determine the kinetic of IFN-b gene induction. TLR2
agonists induced IFN-b transcription with a rapid kinetic (peak at
2–3 h). This fast response was comparable to that by Poly:IC
(TLR3 ligand) which is known to activate IFN-b directly (Fig. 2A).
As depicted below, rapid IFN-b induction upon TLR2 activation
was also evident in vivo (Fig. 3A, C and Fig. S2A). Nonetheless, to
compellingly test whether IFN-b induction is independent of de
novo protein synthesis, cells were stimulated with TLR2 and TLR3
agonists in the presence or absence of the protein synthesis
inhibitor cycloheximide (CHX). In spite of complete inhibition of
protein synthesis, as depicted by the absence of NO and IL-6 in
Figure 2. TLR2 activation induces IFN-b transcription independent of an auto/paracrine loop. In A, BMDMs were stimulated with either
MALP-2 (1.5 mg/ml) or Poly I:C (5 mg/ml) for the indicated time periods then analyzed by quantitative real time RT-PCR for IFN-b mRNA. B–D; TLR2
driven IFN-b induction is independent of an auto/paracrine mechanisms. BMDMs pre-treated for 1 h with or without 0.5 mg/ml CHX were stimulated
for 6 h with either MALP-2 (1.5 mg/ml) or Poly I:C (5 mg/ml) then analyzed by real-time RT-PCR for IFN-b (B, please note logarithmic scale) and TNF-a
(C). Culture supernatants of cells stimulated in parallel for 24 hours in the presence of cycloheximide were analyzed for nitric oxide (D). Data are
representative of three independent experiments (mean 6 s.e.m).
doi:10.1371/journal.pone.0010250.g002
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ligands still induced the transcription of IFN-b and TNF-a in the
presence of CHX (Fig. 2B–C). Thus, much like TLR3, activation
of TLR2 does induce both pro-inflammatory and IFN-b responses
directly.
TLR2-driven IFN-b induction in vivo
To investigate TLR2-driven type I IFN responses in vivo, WT,
TLR2
2/2 and IFNAR
2/2 mice were inoculated with the TLR2
ligand PAM3CSK4 and then analyzed for secretion of IFN-b and
type I IFN-dependent mediators. ELISA assay readily revealed an
accumulation of IFN-b in the serum of IFNAR
2/2 but not
TLR2
2/2 or WT mice (Fig. 3A and data not shown). This is
consistent with the in vitro data showing that upon TLR triggering,
IFN-b is secreted which in turn binds to and is thus removed from
the system via IFNAR. Indeed, further analysis revealed elevated
levels of IP-10 and NO in WT but not in TLR2
2/2 or IFNAR
2/2
mice (Fig. 3B and data not shown).
To monitor the in vivo induction of IFN-b in more details, we
constructed a transgenic IFN-b-luciferase reporter mouse (Db-
luc)[19]. In these mice, the IFN-b gene was replaced by the firefly
luciferase. For the present analysis, we used Db-luc heterozygous
mice containing a functional IFN-b allele and a luciferase
expression cassette (TLR2
+/+IFN-b
+/D-luc). For control, the Db-luc
mice were crossed with TLR2
2/2 mice to generate TLR2
2/2IFN-
b
+/D-luc mice. When challenged with MALP-2 or PAM3CSK4,
TLR2
+/+IFN-b
+/D-luc mice responded with luminescence while
mice lacking TLR2 (Fig. 3C and Fig. S2A). Consistent with the
Figure 3. TLR2-driven IFN-b and type I IFN dependent responses in vivo. A–B; Five mice per group WT, TLR2
2/2 and IFNAR
2/2 were injected
with control medium or PAM3CSK4 (100 mg/mouse) then sacrificed at different time points between 0–18 hours and their sera (A) or peritoneal
exudates (B) analyzed by ELISA for IFN-b and IP-10 respectively Data representative of two independent experiment show 6 s.e.m. C; Three mice per
group of TLR2
+/+IFN-b
+/D-luc (TLR2
+/+) and TLR2
2/2IFN-b
+/D-luc (TLR2
2/2) mice were injected with MALP-2 (100 mg/mouse) and expression of luciferase
was monitored for 24 h by luminescence imaging. C shows two representative mice out of a group of four mice before (0 hours) and after (3 hours)
MALP-2 administration. Fold increase and kinetics of luciferase induction of corresponding mice are depicted in Fig. S2A. D–I; TLR2 mediated IFN-b
induction in macrophages. Macrophages matured from bone marrows of TLR2
+/+IFN-b
+/D-luc or TLR2
2/2IFN-b
+/D-luc mice were stimulated with
indicated concentrations of MALP-2 (D, G) or PAM2CSK4 (E, H) or PAM3CSK4 (F, I) for 4 hours and analyzed for luciferase expression. D–F; show
representative luminescence images of macrophages while G–I indicate the fold increase in luciferase in corresponding cells. Luciferase expression is
represented by a colour shift from blue to red. Similar results were obtained from three independent experiments (mean 6 s.e.m). Note that the
background response in reporter mice, mainly in the liver region, might be due to the liver’s role in trapping and detoxifying noxious substances from
the system. Such substances and the metabolic products thereof could account for the higher MALP-2 associated background in TLR22/2 mice.
doi:10.1371/journal.pone.0010250.g003
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peak of the in vivo IFN-b response by such TLR2 ligands was also
3-4 hours post stimulation (Fig. 3C and Fig. S2A).
Over the years it had been suggested that only the TLR9
subfamily (TLR7, TLR8 and TLR9) could activate type I IFNs via
MyD88. In fact, even the MyD88 pathways for IFN induction by
such TLRs was believed to be functional only in plasmacytoid
dendritic cells (pDCs) [20,21]. However recently Mancuso and co-
workers were able to demonstrate a role for TLR7-MyD88
dependent pathway of type I IFN induction in conventional DCs
in response to group B streptococcus [22]. To investigate whether
the TLR2-MyD88 pathway of IFN-b induction is also functional
in other cell types, peritonial macrophages, bone marrow derived
macrophages (BMDM) and dendritic cells (BMDCs) were also
tested in an in vitro stimulation assay with graded concentrations of
TLR2 and TLR4 agonists. TLR2 agonists were found to induce
luciferase in both, macrophages and DCs from TLR2
+/+ but not
TLR2
2/2 mice (Fig. 3D–I and Fig. S2B and data not shown).
Incontrast, LPSinducedresponsesinboth,TLR2
+/+ and TLR2
2/2,
cells (Fig. S2C&D). Furthermore, LPS stimulation depicted
stronger responses as compared to TLR2 which is consistent with
the activation of the TRIF pathway associated with very strong type
I IFN induction.
In a recently study, Barbalat and co-workers also proposed
TLR2 - dependent type I IFN production only in response to viral
but not toward bacterial ligands. The authors also proposed that
such responses were only feasible in inflammatory monocytes [18].
The functional role of inflammatory monocytes in the study in
question was based on depletion of cells expressing CD11b - a
molecule generally expressed on several cell types including
monocytes, macrophages, granulocytes, and dendritic cells. This
raises the possibility that such responses were in fact the sum of
several cell types and not just inflammatory monocytes. Whichever
the case and in view of our findings it can safely be concluded that
TLR2 pathway of IFN-b induction is functional in several host cell
types and that this pathway is not a preserve of viral activation but
rather a consequence of TLR2 activation by various ligands
including those from bacteria, mycoplasma and possibly fungi and
protozoa.
TLR2 induces type I IFN-b via IRF1 and IRF7
The transcription of IFN-a/b is primarily controlled by the IRF
family of transcription factors. To elucidate the IRFs downstream
of the TLR2-MyD88 pathway of IFN-b induction, we investigated
the role of IRF1, IRF3 and IRF7. These transcription factors have
been implicated as positive regulators of the transcription of type I
IFN genes [23]. Macrophages from IRF1
2/2 and IRF7
2/2 mice
were highly diminished in IFN-b production following stimulation
with TLR2 ligands, while IRF3
2/2 macrophages had a normal
response (Fig. 4A–C). Based on the present data, TLR2 activation
induces type I IFN responses via MyD88-IRF1 and -IRF7
pathways. These findings suggest that the TLR2-driven pathway
of type I IFN induction is in a way similar to that by the TLR9
subfamily of TLRs also shown to trigger MyD88-IRF1 and -IRF7
pathways [22,24,25,26,27].
TLR2 induces IFN-b from endolysosomes
One of the emerging themes in the induction of type I IFNs is
the intracellular localization of receptors. Potent inducers of type I
IFNs like TLR3, TLR7/8, TLR9, RIG-I, MDA5, DAI, are all
intracellular receptors that sense nucleic acids located in the
endosome or cytosol [5,8]. Using confocal microscopy, we first
studied the sub-cellular localization of TLR2-GFP in transiently
transfected RAW 264.7 macrophages. Consistent with previous
observations [28], in unstimulated cells, TLR2-GFP was found to
be localized either at the plasma membrane or in the perinuclear
region (most likely in ER and trans-golgi networks) and hardly co-
localized with the endolysosomal markers lysotracker or dextran
(Fig. 5A and Fig. S3A). However by 3 h after MALP-2
stimulation, TLR2 was found enriched in clusters which co-
localized with lysotracker or Dextran (Fig. 5B and Fig. S3B).
Such co-localization was however severely impaired when the
endocytic maturation pathway was blocked using Bafilomycin A
(BafA), an inhibitor of the endosomal proton pump (Fig. 5C and
Fig. S4C). These observations suggest that TLR2 activates
endocytic internalization and endosome maturation, as proposed
previously [29,30,31].
To investigate a potential link between the translocation of
TLR2 into endolysosomal compartments and the induction of
type I IFN responses, macrophages were stimulated with TLR2
ligands in the presence of Cytochalasin D (CytD). CytD blocks
endocytic internalization by inhibiting actin polymerization. CytD
almost completely inhibited the induction of IFN-b and type I
IFN-inducible genes (IP-10, and iNOS) by TLR2 ligands (Fig. 6A–
C). In addition to blocking receptor internalization and vesicular
trafficking, CytD may also interfere with other signalling processes.
Therefore, we resorted to a more specific inhibitor of the endocytic
maturation pathway: Bafilomycin A (BafA). BafA inhibits the
endosomal proton pump hence endosome acidification and
subsequent fusion with lysosomes. BafA severely inhibited the
TLR2 driven IFN-b and type I IFN dependent responses but not
the pro-inflammatory responses (Fig. 6D–F). Similar results were
obtained with Dynasore (Dyn), an inhibitor of the endocytic
effector protein dynamin (Fig. S4). Collectively, these data suggest
that TLR2 induces pro-inflammatory cytokines like TNF-a from
the plasma membrane while IFN-b is triggered from endolysoso-
mal compartments after receptor internalization.
Figure 4. TLR2 activation induces type I IFN-b via IRF1 and IRF7.
A–C, WT, TLR2
2/2, IRF1
2/2, IRF3
2/2,a n dIRF7
2/2 BMDMs were
stimulated with ligands for TLR2/6 (1.5 mg/ml MALP-2 or PAM2CSK4)
or TLR2/1 (1.5 mg/ml PAM3CSK4). After 10 hours, supernatants were
analyzed for IFN-b by ELISA. Similar data represent an average of two
independent experiments (mean 6 s.e.m, *: p,0.05).
doi:10.1371/journal.pone.0010250.g004
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So far, the signalling model for the TLR2 subfamily of TLRs
has been based on the dogma that these receptors induce pro-
inflammatory cytokines but not type I interferons upon activation
by bacterial ligands. Using different in vitro and in vivo approaches,
we now show that in addition to pro-inflammatory cytokines,
TLR2 heterodimers also elicit interferon-b and hence type I
interferon dependent responses. Interestingly, the induction of
pro-inflammatory responses and type I interferons by TLR2
ligands occur from distinct sub-cellular sites: the plasma mem-
brane and endolysosomal compartments, respectively.
As schematically illustrated in Fig. 6G, our results suggest a
new model for TLR2 signalling. We propose that analogous to
that for TLR4, TLR2 activation at the plasma membrane first
induces the MyD88-NF-kB-dependent pathway. This activates
not only the transcription of genes encoding pro-inflammatory
cytokines but also induces endocytic internalization and trafficking
of the TLR2 complex into endolysosomal compartments, where it
additionally activates MyD88-dependent IRF1 and IRF7 path-
ways for IFN-b induction. Consequently, as we have shown,
pharmacological blockers of receptor internalization and endo-
some maturation are able to inhibit the induction of type I
interferons but not pro-inflammatory cytokines upon TLR2.
Type I IFNs support the transcription of several mediators that
promote protection against microbes. Some of the type I IFN-
inducible mediators such as IP-10 and NO, herein shown to be
induced in response to TLR2 activation play an important role not
only in the activation and recruitment of inflammatory cells to sites
of infection but also have direct anti-microbial effects. For
example, TLR2-driven NO production, is known to be critical
for protective immunity against Toxoplasma gondii [32]. Similarly,
NO production, also a critical protective component against
mycoplasmas [33], is known to be largely due to TLR2 activation
by MALP-2 or its homologs [34,35].
In a recent study, Barabalat and co-workers reported a role for
TLR2 in the recognition of vaccinia virus [18]. However since
such studies employed UV irradiated virus particles, incapable of
activating cytosolic signalling pathways, whether type I IFN
responses induced by vaccinia virus are mainly due to TLR2
activation as proposed [18], as opposed to the TLR independent
cytosolic pathways as reported by Zhu and others [36] remains to
be resolved. Nonetheless, together with the present findings it is
clear that although so far ignored, TLR2–driven pathway of type I
IFN induction is a crucial component of host defences against a
variety of microbes.
The mechanistic explanation for the induction of type I IFNs
from endolysosomal compartments by TLR2 is not clear at the
present. However, we are tempted to speculate that such
intracellular compartments could serve as docking sites on which
key signalling molecules involved in type I IFN induction are
marshalled to a sufficient concentration to mediate downstream
signalling processes. We also infer that the acidic environment in
endolysosomal compartments probably facilitates conformational
Figure 5. Ligand induced internalization and trafficking of TLR2 into endolysosomal compartments. RAW 264.7 macrophages
transfected with hTLR2-GFP were labelled with lysotracker then left untreated (A) or stimulated with 1 mg/ml of MALP-2 and imaged by confocal
microscopy after 3 h (B). Panel C shows cells first labelled with lysotracker then incubated for 1 hour with 50 mM Bafilomycin A before stimulation
with MALP-2. The co-localization fluorographs displayed in the right panels show the intensities and scatter pattern of all pixels within the merged
images. Pixels with mostly one fluorescent component are placed along the axes 1 and 2 while the pixels with equal fluorescence intensity from both
components (due to co-localization) are placed along the diagonal. Axis 1 and 2 show the green (TLR2-GFP) and red (Lysotracker) fluorescence
intensities on an arbitrary scale of 0 to 250.
doi:10.1371/journal.pone.0010250.g005
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adaptors, kinases and IRFs. In line with this hypothesis, DNA
structures that target different endocytic compartments are known
to induce distinct biological responses [21,37,38], and have been
shown to trigger different conformational changes in TLR9 [39].
A more recent study showing that proteolytic processing of TLR7
and TLR9 by endolysosomal proteases is a prerequisite for their
signalling [40] is also consistent with the above idea. Additional
studies are required to provide more mechanistic insights into how
intracellular localization and an acidic environment facilitate the
induction of type I IFNs by TLRs and other PRRs.
Finally, our results have clinical implications. Although the TLR
triggering does mediate protective host responses against microbes,
excessive production of pro-inflammatory cytokines and type I
IFNs due to such activation is known to inflict severe self-injury.
Thus the discovery that pro-inflammatory and type I IFN
responses are induced from distinct sub-cellular sites and that
these two responses can be uncoupled by properly manipulating
Figure 6. Blockers of receptor internalization and endosome maturation pathways abrogate TLR2 driven type I IFN responses.
BMDM, untreated or pre-treated with either 25 mM Cytochalasin D (A–C) or 50 mM Bafilomycin A (D–F) for 1 hour, were stimulated with 1.5 mg/ml of
the indicated TLR2 ligands. After 6 h cell pellets were analyzed by quantitative real-time RT-PCR for IFN-b (A and D). Supernatants of cells stimulated
in parallel for 24 hours were also analyzed for Nitric Oxide (Nitrite) by Griess reaction (B and E) or for TNF-a. Data represent similar results from three
independent experiments (mean 6 s.e.m, *: p,0.05). G; Model for TLR2 signaling. Upon ligand engagement at the plasma membrane TLR2 activates
a MyD88-NF-kB pathway leading to the induction of pro-inflammatory cytokines like TNF-a and IL-12. The initial trigger at the plasma membrane also
induces endocytic internalization and transportation of the TLR2 complex into endolysosomal compartments from where it activates MyD88-IRF1/
IRF7 pathways of IFN-b induction. Once produced, IFN-b in turn activates STAT1 which alone or in synergy with other transcription factors like NF-kB
activates the transcription of IFN-inducible genes; Mx-2, IP-10, iNOS, IL-6.
doi:10.1371/journal.pone.0010250.g006
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potential therapeutic intervention against inflammations.
Materials and Methods
Ethics statement
All mice were maintained under pathogen free conditions and
experiments were approved and carried out according to the
guidelines set out by LAVES (Niedersaechsisches Landesamt fu ¨r
Verbraucherschutz und Lebensmittelsicherheit).
Mice
C57BL/6 mice were purchased from Harlan- Germany.
IRF1
2/2[41], IFNAR
2/2 [42] and IFN-b
2/2 [43] mice were
bred in our animal facility. TLR2
2/2 [44] and MyD88
2/2 [45]
mice, originally generated in Dr. S Akira’s laboratory, were
obtained from MPI-Berlin. IRF3
2/2[46], and IRF7
2/2 [25] mice
were obtained from Dr. T. Decker (University of Vienna, Austria)
with permission from Dr. T. Taniguchi (University Tokyo, Japan).
The transgenic IFN-b-luciferase reporter mice (Db-luc) [19] were
generated by replacing IFN-b with the firefly luciferase using the
standard homologous recombination protocol. The Db-luc mice
were then backcrossed to TLR2
2/2 mice [44] to generate
TLR2
-/-IFN-b
+/D-luc and TLR2
+/+IFN-b
+/D-luc mice.
Reagents
MALP-2 was a kind gift from Dr. Werner Tegge, HZI.
PAM2CSK4, PAM3CSK4, and LPS Salmonella minnesota were
from Invivogen. Poly I:C was from Amersham Biosciences.
Cytochalasin D was purchased from FLUKA, Cycloheximide,
Bafilomycin A and Dynasore were purchased from Sigma.
Cells
Bone marrow derived macrophages were cultured for 7 days in
the presence of M-CSF and bone marrow derived dendritic cells
were cultured for 10 days in the presence of GM-CSF and IL-4
according to standard protocols.
Cell transfection and confocal imaging
hTLR2-GFP was bought from Invivogen. RAW 264.7 cells
were transiently transfected using MicroPorator (PM-100) accord-
ing to the manufacturer’s instructions. hTLR2-GFP transfected
cells were loaded with 1 mM of Lysotracker Red DND-99 or
Dextran-Alexa Fluor 647 (both from Invitrogen) for 30 minutes,
washed, then incubated with Bafilomycin A (in some cases) before
stimulation with TLR2 ligands. Confocal imaging was done as
described previously [47].
Cytokine Assays
Supernatants were analyzed by ELISA using rat anti-mouse IL-
12p70 and rat anti-mouse IL-6 antibodies together with the
respective recombinant mouse IL-6 and IL-12 standards from BD
Pharmingen. The IFN-b ELISA kit was purchased from PBL
Biomedical Laboratories and the IP-10 ELISA was from Bender
MedSystems. Both were performed according to the manufactur-
er’s instructions. Nitric oxide was detected using the Griess reagent
kit (Promega).
In vivo luciferase assays
Mice were injected intraperitoneally with TLR2 ligands. At
different time points, mice were anaesthetized with isoflurane
using the XGI-8 gas anaesthesia system (Caliper). Prior to image
acquisition 3 mg of luciferin (Caliper) dissolved in 100 ml PBS was
injected intraperitoneally. Images were obtained at consecutive
time points thereafter using the IVIS-200 system (Caliper)
according to instructions of the manufacturer. The software
Living image 3.0 (Caliper) was used for image analysis and
quantification of emission intensities.
In-vitro luciferase assays
Cells were stimulated with TLR2 agonists for 4 hours. The cells
were lysed in Reporter Lysis Buffer (Promega). 5 ml of cell lysate
was added to 25 ml of Luciferase Assay Reagent II (Promega) and
Images were obtained using the IVIS-200 system (Caliper)
Luminescence was quantified as described above.
Statistical analysis
Data in the text and figures are expressed as the mean +/2 SD.
Statistical comparisons were carried out using the Student’s t-test.
P values less than 0.05 were considered significant.
PCR
RNA extraction was performed with the Quiagen Rneasy Mini
Kit according to the manufacturer’s instructions. RT-PCR was
performed with the GoTaq Flexi DNA Polymerase from Promega
and Real time PCR was carried out using Power SYBR Green
PCR Master Mix from Applied Biosystems with the following
primers (operon):
TNF-a sense (59-TCTCATCAGTTCTATGGCCC-39),
TNF-a antisense (59-GGGAGTAGACAAGCTACAAC-39),
IP-10 sense (59-GATGACGGGCCAGTGAGAATGAG-39),
IP-10 antisense (59-CTGGGTAAAGGGGAGTGATGGAG-
A-39),
Mx-2 sense (59-GAGAATGTCGCCTATTCACCAGGCTC-
39),
Mx-2 antisense (59-GCCATGGATGAGGTCTGTAAATC-
TTGGG-39),
IFN-b sense (59-CATCAACTATAAGCAGCTCCA-39),
IFN-b antisense (59-TTCAAGTGGAGAGCAGTTGAG-39),
RPS9 sense (59-CTGGACGAGGGCAAGATGAAGC-39)
and RPS9 antisense (59-TGACGTTGGCGGATGAGCAC-
A-39).
Supporting Information
Figure S1 TLR2 activation induces type I IFN dependent
responses via MyD88. WT, TLR2
2/2, MyD88
2/2, IFN-b
2/2 and
IFNAR1
2/2 macrophages were stimulated (or unstimulated) with
1.5 mg/ml of MALP-2, PAM2CSK4 or PAM3CSK4. After
24 hours respective culture supernatants were analyzed for IL-6
by ELISA (A) or Nitric oxide/Nitrite by Griess reaction (B). Data
are representative of more than four independent experiments
(mean 6 s.e.m.).
Found at: doi:10.1371/journal.pone.0010250.s001 (1.41 MB TIF)
Figure S2 In vivo and in vitro analysis of IFN-b induction using
the Luciferase reporter system. A shows the kinetics of IFN-b
induction in TLR2
+/+IFN-b
+/Db-luc (TLR2
+/+) and TLR2
2/2IFN-
b
+/Db-luc (TLR2
2/2) mice injected with MALP-2 (*: p,0.05). The
corresponding luminescence images are depicted in Fig. 3C–D.
Dendritic cells (BMDCs) or macrophages (BMDMs) derived from
TLR2
+/+IFN-b
+/Db-luc (TLR2
+/+) and TLR2
2/2IFN-b
+/Db-luc
(TLR2
2/2) mice were stimulated with indicated concentrations
of MALP-2 or LPS for 4 hours and analyzed for luciferase
expression. B shows quantification of fold increase in luciferase
expression (i.e., IFN-b induction) in BMDCs (mean 6 s.e.m.). C
show representative luminescence images of macrophages while D
TLR2-Driven Type I IFNs
PLoS ONE | www.plosone.org 8 April 2010 | Volume 5 | Issue 4 | e10250indicates the fold increase in luciferase in corresponding cells
(mean 6 s.e.m.). Note that the luminescence colour scale bar for
LPS and MALP-2 are different.
Found at: doi:10.1371/journal.pone.0010250.s002 (3.10 MB TIF)
Figure S3 Ligand induced internalization and trafficking of
TLR2 into endolysosomal compartments. RAW 264.7 macro-
phages transfected with hTLR2-GFP were loaded with fluorescent
Dextran-Alexa Fluor 647, then left untreated (A) or stimulated
with 1.5 mg/ml of MALP-2 and imaged by confocal microscopy
after 3 hours (B). Panel C shows cells first labelled with Detran-
Alexa and then pre-incubated for 1 h with 50 mM Bafilomycin A
before stimulation with MALP-2 for 3 hours.
Found at: doi:10.1371/journal.pone.0010250.s003 (1.38 MB TIF)
Figure S4 Dynasore,aninhibitorofdynamin1,abrogatesTLR2-
driven IFN-b induction. BMDM from TLR2
+/+IFN-b
+/Db-luc mice
pre-incubated for 1 h with indicated concentrations of Dynasore
were stimulated with or without 1.5 mg/ml of MALP-2 for 4 h
and analyzed for luciferase expression. A shows representative
luminescence images of stimulated macrophages while B indicates
the corresponding fold increase in luciferase activity. Luciferase
expression is represented by a colour shift from blue to red.
Data represent similar results from two independent experiments
(mean 6 s.e.m.). *: p,0.05 indicate statistical significance in the
deference between Dynasore treated and untreated cells that were
stimulated with MALP-2.
Found at: doi:10.1371/journal.pone.0010250.s004 (3.00 MB TIF)
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